Journal
IMMUNOTHERAPY
Volume 9, Issue 16, Pages 1309-1321Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2017-0096
Keywords
cancer immunotherapy; cytokine; electroporation; gene therapy; IL-12; ImmunoPulse (R); IL-12; ImmunoPulse (R); IT-tavo-EP; melanoma; pIL-12
Categories
Funding
- OncoSec
Ask authors/readers for more resources
Tumors evade detection and/or clearance by the immune system via multiple mechanisms. IL-12 is a potent immunomodulatory cytokine that plays a central role in immune priming. However, systemic delivery of IL-12 can result in life-threatening toxicity and therefore has shown limited efficacy at doses that can be safely administered. We developed an electroporation technique to produce highly localized IL-12 expression within tumors leading to regression of both treated and untreated lesions in animal models and in patients with a favorable safety profile. Furthermore, intratumoral tavokinogene telseplasmid electroporation can drive cellular immune responses, converting 'cold' tumors into 'hot' tumors. Clinical trials are ongoing to determine whether intratumoral tavokinogene telseplasmid electroporation synergizes with checkpoint blockade therapy in immunologically cold tumors predicted not to respond to PD-1 antibody monotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available